CO6751269A2 - Métodos para controlar el dolor en caninos usando una solución transdermal de fentanilo - Google Patents

Métodos para controlar el dolor en caninos usando una solución transdermal de fentanilo

Info

Publication number
CO6751269A2
CO6751269A2 CO13199507A CO13199507A CO6751269A2 CO 6751269 A2 CO6751269 A2 CO 6751269A2 CO 13199507 A CO13199507 A CO 13199507A CO 13199507 A CO13199507 A CO 13199507A CO 6751269 A2 CO6751269 A2 CO 6751269A2
Authority
CO
Colombia
Prior art keywords
fentanyl
methods
transdermal solution
control canine
composition
Prior art date
Application number
CO13199507A
Other languages
English (en)
Inventor
Garret Conrad Newbound
Terrence Patrick Clark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6751269A2 publication Critical patent/CO6751269A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para controlar dolor en un canino que comprende administrar transdermalmente una composición que comprende fentanilo, un intensificador de penetración, y un líquido volátil, en donde la composición es una solución. La invención también proporciona una dosis unitaria única de la composición.
CO13199507A 2011-02-15 2013-08-22 Métodos para controlar el dolor en caninos usando una solución transdermal de fentanilo CO6751269A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161442884P 2011-02-15 2011-02-15

Publications (1)

Publication Number Publication Date
CO6751269A2 true CO6751269A2 (es) 2013-09-16

Family

ID=45615076

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13199507A CO6751269A2 (es) 2011-02-15 2013-08-22 Métodos para controlar el dolor en caninos usando una solución transdermal de fentanilo

Country Status (21)

Country Link
US (1) US8603984B2 (es)
EP (1) EP2675453B1 (es)
JP (1) JP2014505726A (es)
KR (1) KR101526781B1 (es)
CN (1) CN103384524A (es)
AU (1) AU2012218007B2 (es)
BR (1) BR112013020775A2 (es)
CA (1) CA2827435C (es)
CL (1) CL2013002322A1 (es)
CO (1) CO6751269A2 (es)
DK (1) DK2675453T3 (es)
EA (1) EA201391023A1 (es)
ES (1) ES2688288T3 (es)
HU (1) HUE041353T2 (es)
IL (1) IL227292A0 (es)
MX (1) MX2013009468A (es)
PL (1) PL2675453T3 (es)
PT (1) PT2675453T (es)
SG (1) SG192782A1 (es)
WO (1) WO2012112348A1 (es)
ZA (1) ZA201305341B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110092922A1 (en) * 2009-10-19 2011-04-21 Trompen Mick A Transdermal dispensing apparatus and methods
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0629191B2 (ja) * 1984-09-04 1994-04-20 株式会社ポリトロニクス 抗腫瘍剤、抗ウィルス剤
BR9105371A (pt) * 1990-12-20 1992-08-25 Lilly Co Eli Formulacao apropriada para a administracao transdermica de dobutamina e processo para aumentar a contratilidade cardiaca
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AR032545A1 (es) * 2001-02-08 2003-11-12 Schering Plough Ltd Composiciones parasiticidas y metodos de uso
BRPI0312007B1 (pt) 2002-06-25 2015-04-14 Acrux Dds Pty Ltd Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição
AUPS317102A0 (en) 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
JP2004123545A (ja) * 2002-09-30 2004-04-22 Sumitomo Chem Co Ltd 動物外部寄生虫防除用経皮投与剤
US7309593B2 (en) 2003-10-01 2007-12-18 Surmodics, Inc. Attachment of molecules to surfaces
WO2005051476A1 (en) 2003-11-28 2005-06-09 Acrux Dds Pty Ltd Method and system for rapid transdermal administration
WO2009047779A2 (en) 2007-06-20 2009-04-16 Nikki Nikhilesh Singh Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
SG176616A1 (en) 2009-07-01 2012-01-30 Locata Corp Method and apparatus for forming a beam
US20110092922A1 (en) 2009-10-19 2011-04-21 Trompen Mick A Transdermal dispensing apparatus and methods

Also Published As

Publication number Publication date
DK2675453T3 (en) 2018-10-29
ES2688288T3 (es) 2018-10-31
NZ613021A (en) 2015-02-27
CA2827435C (en) 2018-11-27
PT2675453T (pt) 2018-11-07
CL2013002322A1 (es) 2013-12-27
MX2013009468A (es) 2013-09-06
HUE041353T2 (hu) 2019-05-28
EP2675453A1 (en) 2013-12-25
WO2012112348A1 (en) 2012-08-23
AU2012218007B2 (en) 2015-08-06
IL227292A0 (en) 2013-09-30
EP2675453B1 (en) 2018-08-08
KR20130116331A (ko) 2013-10-23
JP2014505726A (ja) 2014-03-06
ZA201305341B (en) 2015-01-28
BR112013020775A2 (pt) 2016-10-11
EA201391023A1 (ru) 2014-01-30
KR101526781B1 (ko) 2015-06-05
CA2827435A1 (en) 2012-08-23
SG192782A1 (en) 2013-09-30
CN103384524A (zh) 2013-11-06
US8603984B2 (en) 2013-12-10
PL2675453T3 (pl) 2018-12-31
US20120208849A1 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
BR112012032579A2 (pt) "terapia de diabetes"
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
BR112012023021A2 (pt) compostos de indazol e seus usos
EA201590450A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CL2014001515A1 (es) Uso de dexmedetomidina o una sal de ella para tratar o prevenir el dolor sin sedacion importante tal como dolor idiopatico; y dispositivo de dosis medida que comprende una composicion farmaceutica con dexmedetomidina.
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112014015955A2 (pt) uso terapêutico subcutâneo de inibidor de dpp-4
CL2015002534A1 (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
SMT201500184B (it) Sistema terapeutico transdermico per somministrareun principio attivo
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
CO6751269A2 (es) Métodos para controlar el dolor en caninos usando una solución transdermal de fentanilo
MY181540A (en) Transdermal composition containing donepezil as active ingredient
BR112016006848A2 (pt) métodos e composições para distribuição transdérmica de uma quantidade não sedativa de dexmedetomidina
EA201591124A1 (ru) Трансдермальная система доставки
PE20120791A1 (es) Composiciones y metodos para terapia prolongada con aminopiridinas
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
CL2012003152A1 (es) Composicion farmaceutica para ser usada en terapia de reemplazo de glucocorticoides mediante la administracion oral una vez al dia de una dosis equivalente a la hidrocortizona de acuerdo con un nomograma de peso o un nomograma farmacocinetico; metodo de tratamiento; metodo para derivar una dosificacion individualizada.
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
AR092713A1 (es) Composiciones y metodos de uso de un compuesto para el control de la inapetencia
BR112013016615A2 (pt) uso de dronedarona para a preparação de um medicamento para uso no controle do risco de lesão hepática
NI201500007A (es) Formulación transdérmica que contiene inhibidores de cox
MY162831A (en) Once-a-day replacement transdermal administration of fentanyl